Literature DB >> 27347057

Regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor-α genetic variations.

Yangzhou Liu1, Ning Han1, Qinchuan Li1, Zengchun Li1.   

Abstract

The present study aimed to investigate the regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor (TNF)-α genetic variations. The GSE5760 expression profile data, which was downloaded from the Gene Expression Omnibus database, contained 30 wild-type (WT) and 28 mutation (MUT) samples. Differentially expressed genes (DEGs) between the two types of samples were identified using the Student's t-test, and the corresponding microRNAs (miRNAs) were screened using WebGestalt software. An integrated miRNA-DEG network was constructed using the Cytoscape software, based on the interactions between the DEGs, as identified using the Search Tool for the Retrieval of Interacting Genes/Proteins database, and the correlation between miRNAs and their target genes. Furthermore, Gene Ontology and pathway enrichment analyses were conducted for the DEGs using the Database for Annotation, Visualization and Integrated Discovery and the KEGG Orthology Based Annotation System, respectively. A total of 390 DEGS between the WT and MUT samples, along with 11 -associated miRNAs, were identified. The integrated miRNA-DEG network consisted of 38 DEGs and 11 miRNAs. Within this network, COPS2 was found to be associated with transcriptional functions, while FUS was found to be involved in mRNA metabolic processes. Other DEGs, including FBXW7 and CUL3, were enriched in the ubiquitin-mediated proteolysis pathway. In addition, miR-15 was predicted to target COPS2 and CUL3. The results of the present study suggested that COPS2, FUS, FBXW7 and CUL3 may be associated with sepsis in patients with TNF-α genetic variations. In the progression of sepsis, FBXW7 and CUL3 may participate in the ubiquitin-mediated proteolysis pathway, whereas COPS2 may regulate the phosphorylation and ubiquitination of the FUS protein. Furthermore, COPS2 and CUL3 may be novel targets of miR-15.

Entities:  

Keywords:  microRNA; microarray data; sepsis; tumor necrosis factor-α variation; ubiquitination

Year:  2016        PMID: 27347057      PMCID: PMC4906948          DOI: 10.3892/etm.2016.3308

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  40 in total

Review 1.  Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations.

Authors:  R A Balk
Journal:  Crit Care Clin       Date:  2000-04       Impact factor: 3.598

2.  Insights into the molecular mechanisms in sepsis with microarray technology.

Authors:  F-S Qiao; C Wei; J Yun; L-X Qian
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

Review 3.  Therapeutic intervention and targets for sepsis.

Authors:  Todd W Rice; Gordon R Bernard
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

4.  Targeting transmembrane TNF-α suppresses breast cancer growth.

Authors:  Mingxia Yu; Xiaoxi Zhou; Lin Niu; Guohong Lin; Jin Huang; Wenjing Zhou; Hui Gan; Jing Wang; Xiaodan Jiang; Bingjiao Yin; Zhuoya Li
Journal:  Cancer Res       Date:  2013-06-21       Impact factor: 12.701

5.  Prediction of feature genes in trauma patients with the TNF rs1800629 A allele using support vector machine.

Authors:  Guoting Chen; Ning Han; Guofeng Li; Xin Li; Guang Li; Yangzhou Liu; Wei Wu; Yong Wang; Yanxi Chen; Guixin Sun; Zengchun Li; Qinchuan Li
Journal:  Comput Biol Med       Date:  2015-06-09       Impact factor: 4.589

6.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

Authors:  Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

7.  Elevated levels of plasma TNF-α are associated with microvascular endothelial dysfunction in patients with sepsis through activating the NF-κB and p38 mitogen-activated protein kinase in endothelial cells.

Authors:  Yingjian Liang; Xin Li; Xiaojuan Zhang; Zhiliang Li; Liang Wang; Yini Sun; Zhiyong Liu; Xiaochun Ma
Journal:  Shock       Date:  2014-04       Impact factor: 3.454

Review 8.  The COP9 signalosome.

Authors:  Ning Wei; Xing Wang Deng
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

9.  Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Eva Bentmann; Manuela Neumann; Sabina Tahirovic; Ramona Rodde; Dorothee Dormann; Christian Haass
Journal:  J Biol Chem       Date:  2012-05-04       Impact factor: 5.157

10.  Evaluating different methods of microarray data normalization.

Authors:  André Fujita; João Ricardo Sato; Leonardo de Oliveira Rodrigues; Carlos Eduardo Ferreira; Mari Cleide Sogayar
Journal:  BMC Bioinformatics       Date:  2006-10-23       Impact factor: 3.169

View more
  3 in total

1.  Mortality prediction using a novel combination of biomarkers in the first day of sepsis in intensive care units.

Authors:  Chengwen Bai; Binbin Li; Junkun Liu; Aijun Shan; Fei Shi; Can Yao; Yu Zhang; Jin Wang; Weibu Chen; Manying Xie; Dehui Deng
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

2.  Combining Blood-Based Biomarkers to Predict Mortality of Sepsis at Arrival at the Emergency Department.

Authors:  Yinjing Xie; Binbin Li; Ying Lin; Fei Shi; Weibu Chen; Wenyuan Wu; Wenjia Zhang; Yun Fei; Shiqing Zou; Can Yao
Journal:  Med Sci Monit       Date:  2021-02-25

3.  Integration of gene co-expression analysis and multi-class SVM specifies the functional players involved in determining the fate of HTLV-1 infection toward the development of cancer (ATLL) or neurological disorder (HAM/TSP).

Authors:  Mohadeseh Zarei Ghobadi; Rahman Emamzadeh
Journal:  PLoS One       Date:  2022-01-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.